Bellicum Pharmaceuticals nabs $55 mln Series C

Bellicum Pharmaceuticals has closed $55 million in Series C funding. The investors included funds managed by RA Capital Management, Perceptive Advisors, Jennison Associates (on behalf of certain clients), Sabby Capital and Ridgeback Capital Management. Jefferies was the placement agent. Based in Houston, Bellicum Pharmaceuticals is a biotech firm focused on developing cellular immunotherapies.

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget